China Focus: NPD on calcium, oolong tea, infant formula and more

By Audrey Yow

- Last updated on GMT

China Focus: NPD on calcium, oolong tea, infant formula and more
This edition of China Focus looks at new innovations from Haleon, Danone, and Nestle, including calcium supplements with improved absorption, oolong tea containing an extract shown to lower post-meal blood sugar increase and more.

Calcium supplements: China consumers resonate strongly with absorption benefits, says Haleon

Calcium absorption benefits are resonating strongly with China consumers, and this has been a key revenue driver for Haleon’s bone health supplement business in the first half of 2024.

Revenue of Caltrate grew double digits in the first half of 2024.

The growth was largely due to consumer demand and innovations launched in China, said CEO Brian McNamara.

“This is the year of innovation for China”: Danone to beef up infant formula, FSMP range

Danone is doubling down on its specialised nutrition offerings, including infant formula and Foods for Special Medical Purposes (FSMP) for China, a market which it said has delivered “stellar performance” for the first half of 2024.

Despite China’s declining birth rates and market competition, Danone said it had maintained “competitive momentum” in the market. 

CEO Antoine de Saint-Affrique said that performance in China was driven by both sales volume and new innovations.

'On-the-go innovation': Nestle China’s latest oolong tea contains clinically studied mulberry leaf extract

Nestle China is expanding its range of products containing white mulberry leaf extract clinically shown to reduce postprandial blood sugar increase, with its latest launch a no-sugar Oolong tea.

Each bottle contains 750mg of white mulberry leaf extract, which the company said was clinically proven to “flatten the glucose level”.

Advagen hopes to fill 'white spaces' in China’s postbiotics market

Singapore firm Advagen is expanding into China with the upcoming launch of a postbiotic supplement – a white space in which the company is seeing growth opportunities.

The company, which runs both nutraceutical and pharmaceutical businesses, is known in the regional scene for its gastrointestinal health products.

Mengniu steps up clinical studies on flagship probiotic strain used in yogurt range

China’s Mengniu Dairy is conducting more human clinical studies on Lacticaseibacillus paracasei​ PC-01 – its proprietary probiotic strain used in its Yoyi C yogurt range.

By doing so, the company hopes to revive the concept of yogurt as a nutritious and healthy food, as the dairy product is increasingly designed and consumed as a snack in China these days.

Related topics China

Follow us

Products

View more

Webinars

Nutra Champions Podcast